Latest Pharmx Technologies (Asx:Phx) News

Pharmx Technologies reported a 13% increase in FY25 revenues to $7.53 million, driven by strong growth across its Gateway and Marketplace platforms. The company maintained positive EBITDA and a solid cash position despite legal expenses, setting the stage for an ambitious FY26 growth strategy.

Pharmx Technologies has reported a 13% revenue increase to $7.5 million for FY25, driven by expanded partnerships and platform innovations, despite a dip in EBITDA due to heavy investment.

Pharmx Technologies Limited reported a 13% increase in revenue for FY25, driven by expanded supplier-pharmacy connections and Marketplace platform growth, while profit before tax declined due to significant investments in new technology platforms.

Pharmx Technologies has resumed trading on the ASX following the renewal of its pivotal National Diabetes Services Scheme agreement, signaling stability for the healthcare tech firm.

Pharmx Technologies has extended its pivotal National Diabetes Services Scheme agreement and expanded its supplier base, reinforcing its leadership in pharmacy digital infrastructure across Australia and New Zealand.